Bajaj Consumer Care warns 28% growth is not sustainable despite explosive Q1
Revenue surged 28% YoY to ₹341 cr with record EBITDA margin of 24.7%, but management expects normalization to double-digit/low-teens — and gross margins face fresh stress from the West Asia war.
What's new
- Revenue ₹341 cr, up 28% YoY; EBITDA margin 24.7%, doubling YoY.
- Almond Drop Hair Oil delivered low-teen volume growth on MLP-adjusted basis.
- International business rebounded strongly after a weak FY26.
- Growth portfolio (non-ADHO) now 15% of sales, with Banjara contributing 5%.
Themes from the call
Demand
Broad-based growth across general trade, modern retail, and e-commerce; rural in line with urban.
Margins
Gross margin 61.8%, down 120 bps sequentially but up 510 bps YoY; near-term pressure expected from input cost volatility due to West Asia war.
Distribution
Project Arohan expanding direct-to-outlet model to four new states, delivering 200-300 bps one-time benefit; multiyear architecture shift.
Guidance watch
- Long-term revenue aspiration: consistent double-digit to low-teen growth; current 28% expected to normalize.
- EBITDA margin target: low-to-mid 20s band, with natural quarter-to-quarter variation.
- Q2 gross margin expected slightly more pressured than Q1; easing from Q3.
- Arohan distribution expansion one-time benefit: 200-300 bps on first-time implementation.
Risk flags
- West Asia war creating unprecedented volatility in petroleum derivatives, packaging materials, and edible oils.
- High-cost inventory still in system; spot prices expected to cool only in H2.
- Growth portfolio disclosure pushed to once a year, reducing near-term visibility.
- Management warns 28% growth is exceptional and not a run-rate.
Key quotes
-
"Our aspiration on a long-term basis is to deliver a consistent double-digit performance, double-digit to low teens. If we will not grow that in any quarter, we will be very disappointed, so that is where we stand."
— Naveen Pande, MD -
"We saw our gross margins drop from 63% in the sequentially last quarter to 61.8% in this quarter. ... we see gross margin slightly more under stress in Q2 as compared to Q1."
— Naveen Pande, MD
The brief
Bajaj Consumer Care delivered a blowout quarter: revenue of ₹341 crore, up 28% year-on-year; EBITDA margin of 24.7%, nearly double the year-ago level. The headline numbers suggest a company firing on all cylinders. Almond Drop Hair Oil volume growing in low teens, international business rebounding from a weak FY26, and the growth portfolio (excluding ADHO) now representing 15% of sales. But the story gets complicated when management begins to talk about the future. CEO Naveen Pande explicitly called the 28% growth 'exceptional' and said the long-term aspiration remains 'double-digit to low teens.' That is the same aspiration management cited in January 2026. The contradiction is not just semantic: if 28% is not sustainable, investors need to know what drives the normalization. The numbers do not yet show it. Gross margins tell a different contradiction. In January, management expected copra prices to ease further. On this call, they cited the West Asia war as creating 'unprecedented volatility' in petroleum products, packaging, and edible oils. Gross margin fell 120 basis points sequentially to 61.8%, and management warned Q2 would be even more pressured. The flip-flop on input costs makes it hard to underwrite the margin trajectory. On the positive side, the international business has clearly turned around. Nepal and Bangladesh maintained double-digit growth; MENA and rest-of-world rebounded. The Arohan direct distribution rollout is a multiyear initiative adding 200-300 basis points one-time benefit. But disclosure on the growth portfolio (the non-ADHO businesses that are supposed to diversify the company) has been pushed from a 2-3 quarter timeline to an annual update. That is a loss of transparency for the most strategic part of the story. This is a company that has executed well and posted outstanding numbers. But the messaging is fractured. Management is prudently resetting expectations, but the inconsistencies on revenue aspiration, input cost outlook, and disclosure cadence leave room for skepticism. The verdict: great quarter, cautious guidance, but the input cost reversal demands more explanation. Credibility is on watch.
Bajaj Consumer Care's blowout quarter comes with a caution label and a credibility gap on input costs.